Amoéba Now full speed ahead to commercial launch of its biocontrol solution in ‘26

First-half result numbers overshadowed by the various milestones achieved over the past two years by its biocontrol solution (with final approval of the active substance by the European Commission and the signing of a strategic distribution agreement with Koppert) now enables them to launch its commercialisation in 2026. The US EPA (Environmental Protection Agency) decision on the application for federal marketing authorisation in the US for AXPERA, which has been delayed for reasons beyond Amoéba's own control, is expected in 1Q26.


We also welcome the interest in its cosmetic ingredient, both in France and internationally (recall they are acceleration in the cosmetics segment with a partnership signed with Metron Technology to facilitate the approval and the distribution of its ingredient on the Chinese market). The capital increase carried out in July (strengthened its financial structure and an extended cash horizon, following a successful €14m capital increase in July 2025 (including €5 million through debt offset)) allows them now to transform Amoéba into a fully commercial company. The next important step is the launch of AXPERA with its partner Koppert, while Amoéba is continuing to make advances in cosmetics and the development of new projects like biofertilisers.